The Latest Breaking News from Macular Degeneration

The condition has severely impacted the actress' vision and career

The study's findings provide hope opticians on our high streets could screen for the disease and ultimately prevent cardiac arrests among those affected by the eye condition

According to a recent study from the New York Eye and Ear Infirmary of Mount Sinai, patients with a particular type of age-related macular degeneration (shoppingmode AMD), the main cause of blindness in the United States. Read on for details:

Oscar winner Dame Judi Dench cannot read scripts anymore due to the eye condition know as macular degeneration. Here is a guide for how to best spot the symptoms, and why regular eye tests are so important

The legendary actress has an advanced stage of the condition, which impairs vision

New research shows that the much safer AREDS2 supplement works better at slowing the progress of age-related macular degeneration.

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Better treatments for an eye condition that can cause blindness are a major step closer after scientists discovered genetic clues that show who has it.

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…